Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 4, 2022, Mr. Timothy Jones, the President and Chief Executive Officer
and member of the Board of Directors ("BOD") of RespireRx Pharmaceuticals, Inc.
(the "Company") notified the Company of his intent to resign which he and the
Company subsequently agreed would target January 31, 2022 and would include his
resignation as a member of the BOD.
The BOD intends to appoint Arnold S. Lippa as the Interim President and Interim
Chief Executive effective upon Mr. Jones' departure. The terms of Mr. Jones'
employment agreement, as amended, remain in effect.
The Company has had non-contentious preliminary discussions with Mr. Jones
regarding the timing, transfer of responsibilities, process, expectations during
the transition period through his departure date, as well as related financial
matters. The discussions were preliminary and do not represent final terms,
conditions or processes at this time. If the Company enters into any subsequent
agreement with Mr. Jones regarding the circumstances of his resignation or
departure, the Company will file a subsequent report on Form 8-K.
Mr. Jones indicated in those preliminary discussions that he is resigning to
pursue a consulting practice.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: January 10, 2022 RESPIRERX PHARMACEUTICALS INC.
(Registrant)
By: /s/ Jeff Eliot Margols
Jeff Eliot Margolis
Senior Vice President, Chief
Financial Officer, Secretary and
Treasurer
© Edgar Online, source Glimpses
RESPIRERX PHARMACEUTICALS INC. 
